AKBA
Akebia Therapeutics, Inc.
0.8785$
-3.5%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +2.9% | -6.7% | -2.3% | -5.9% | +6.5% | +40.6% | +11.4% | +5.4% | +3.4% | -3.7% | -3.5% | |
| – | +7.8% | -4.4% | -0.7% | -10.7% | +13.7% | +79.0% | +15.2% | +10.1% | -2.1% | -3.7% | -5.7% | |
| – | -7.7% | -2.2% | -5.9% | -13.9% | +52.5% | +118.6% | +21.1% | +21.2% | +11.1% | -12.0% | -4.4% | |
| – | -7.7% | -2.2% | -5.9% | -13.9% | +52.5% | +118.6% | +21.1% | +21.2% | +11.1% | -12.0% | -4.4% | |
| – | +73.9% | -32.2% | +11.8% | +8.1% | +6.8% | +79.1% | +18.3% | -9.0% | -29.0% | +33.0% | -14.4% | |
| – | -14.9% | +62.7% | -6.5% | -14.2% | -20.7% | +21.5% | -15.3% | +11.6% | -16.3% | -16.7% | +0.2% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -20.0% | -25.0% | -33.3% | -50.0% | – | – | – | – | – | – | – | |
| – | -0.8% | -7.2% | +0.5% | +1.4% | +4.8% | +5.8% | +10.8% | +2.0% | +6.6% | -2.6% | -3.1% | |
| – | +25.3% | -33.4% | +61.4% | -38.8% | +23.1% | +12.7% | +30.1% | +12.4% | +22.2% | +6.7% | -7.5% | |
| – | +71.0% | -76.9% | +41.8% | +4.6% | +29.1% | -43.2% | +2.1% | -12.3% | -28.1% | +252.2% | +98.6% | |
| – | +61.9% | -18.8% | -14.9% | +33.5% | +12.5% | -16.6% | -8.7% | -12.7% | +110.0% | -60.4% | +12.4% | |
| – | -50.4% | +75.4% | +26.2% | +0.9% | +0.9% | +20.2% | +1.2% | +1.2% | +1.3% | -24.6% | -32.0% | |
| – | – | – | – | – | – | – | +18.9% | +42.3% | -21.6% | -16.1% | -8.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.2% | +7.6% | +2.3% | +0.3% | +4.0% | +10.5% | +12.2% | +1.2% | -3.3% | +0.6% | +1.0% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.